Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB

The biopharmaceutical company's stock ownership rises by 82.9% in the third quarter.

Mar. 3, 2026 at 8:47am

Got story updates? Submit your updates here. ›

Handelsbanken Fonder AB, an institutional investor, increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 82.9% in the third quarter of the year, according to a recent SEC filing. The investor now owns approximately 388,369 shares of the biopharmaceutical company's stock, valued at $28.5 million.

Why it matters

Halozyme Therapeutics is a San Diego-based company that specializes in developing drug delivery technologies, particularly its flagship ENHANZE® platform. The increased investment from Handelsbanken Fonder AB suggests growing confidence in the company's technology and future prospects among institutional investors.

The details

According to the SEC filing, Handelsbanken Fonder AB acquired an additional 176,000 shares of Halozyme Therapeutics in the third quarter, bringing its total ownership to approximately 0.33% of the company. The investment firm cited the biopharmaceutical company's promising drug delivery platforms and growth potential as reasons for the increased stake.

  • Handelsbanken Fonder AB increased its stake in Halozyme Therapeutics in the 3rd quarter of 2026.

The players

Handelsbanken Fonder AB

An institutional investor that increased its stake in Halozyme Therapeutics by 82.9% in the third quarter.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in the development and commercialization of novel drug-delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from Handelsbanken Fonder AB in Halozyme Therapeutics suggests that institutional investors see strong growth potential in the company's drug delivery platforms, particularly its flagship ENHANZE® technology. This could signal a positive outlook for the company's future performance and continued innovation in the biopharmaceutical industry.